Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy

BACKGROUND: Dalfampridine improves walking speed in patients with multiple sclerosis (MS), but accessing specialty medications such as dalfampridine can be hindered by insurance restrictions, high costs, and limited distribution networks (LDNs) imposed by manufacturers. Some integrated health-system...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter, Megan E, Markley, Brandon, DeClercq, Josh, Choi, Leena, Givens, Gabrielle, Zuckerman, Autumn D, Banks, Aimee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391274/
https://www.ncbi.nlm.nih.gov/pubmed/33506731
http://dx.doi.org/10.18553/jmcp.2021.27.2.256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391274/
https://www.ncbi.nlm.nih.gov/pubmed/33506731
http://dx.doi.org/10.18553/jmcp.2021.27.2.256

Ejemplares similares